Moderna to present additional Phase 3 melanoma trial data at ESMO 2026

Moderna said detailed Phase 3 results for its personalized cancer therapy will be presented at the ESMO Congress 2026, providing the first detailed look at data from its pivotal melanoma trial that it previously described as a Phase 3 win.